Gene hunt: canagliflozin response studied in 700 volunteers
NCT ID NCT02891954
First seen Jan 11, 2026 · Last updated Apr 24, 2026 · Updated 17 times
Summary
This study looks at how a person's genes might influence their body's response to canagliflozin, a drug used for type 2 diabetes. Healthy volunteers of Amish descent will take the drug for five days, and researchers will measure how much sugar is passed in urine and check other health markers. The goal is to find genetic variations that could help predict who will benefit most from this medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.